Yazar "Zhelezniakova, Natalia M." seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Yayın
    Diagnostic capabilities of kallistatin, IL-10 and IL-1β in patients with non-alcoholic fatty liver disease and hypertension / Alkole bağlı olmayan yağlı karaciğer hastalığı ve hipertansiyonu olan hastalarda kallistatin, IL-10 ve IL1β'nin tanısal güçleri
    (Maltepe Üniversitesi, 2021) Rozhdestvenska, Anastasiia O.; Zhelezniakova, Natalia M.
    Aim: Non-alcoholic fatty liver disease (NAFLD) is closely linked to hypertension (HT) and affects about 25% of the adult population. An important issue remains the search for non-invasive biomarkers for NAFLD diagnosis. The objective of the study was to evaluate the diagnostic value of kallistatin, interleukin-10 (IL-10) and interleukin-1β (IL-β)in diagnosis of NAFLD in combination with HT. Materials and Methods: 115 patients with NAFLD at the stage of non-alcoholic steatohepatitis (NASH) were examined, including 63 patients with comorbidity of NASH and HT (main group) and 52 people with isolated NASH (comparison group).Clinical and laboratory parameters were evaluated; plasma kallistatin, IL-10 and IL-1β levels were measured in all patients. Results: Kallistatin levels averaged 65.03 ng/ml, 83.42 ng/ml and 111.70 ng/ml in patients with NAFLD and HT, isolated NAFLD and control group, respectively. The IL-10 level was 2.69 ng/ml and 4.90 ng/ml in patients with comorbid and isolated NAFLD, respectively, while control results averaged 8.17 ng/ml. The IL1β level in NAFLD and HT group was 4.76 pg/ml, and in isolated NAFLD group the indicator averaged 4.02 pg/ml, which exceeded the control values (0.59 pg/ml). Conclusions: The course of both isolated NAFLD and comorbidity NAFLD with HT was accompanied by significant changes of kallistatin, IL-10 and IL-1β levels. Higher HT stage and BP grade, increased BMI and high CRP levels are associated with significantly more pronounced deviations of these indicators in patients with NAFLD and HT. The obtained data provide the possibility to consider the kallistatin, IL-10 and IL-1β as biomarkers of NAFLD severity.